|1.||Arterial Occlusive Diseases (Arterial Occlusive Disease)
01/01/1991 - "Generation of PGE0 from infused PGE1 may contribute to the clinical efficacy of PGE1 in treatment of severe peripheral arterial occlusive disease."
01/01/1991 - "It is concluded that the beneficial effects of PGE1 in treatment of peripheral arterial occlusive disease are a multifactorial event and might involve PGE0, in particular at intravenous administration of high doses."
01/01/1991 - "The biological activities of PGE0 may contribute to the in vivo effects of PGE1 in treatment of peripheral arterial occlusive disease, in particular at high-dose i.v. administration."
11/01/1995 - "Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels."
11/01/1995 - "1. This study examined whether pretreatment of rabbits with infusions of prostaglandin E1 (PGE1) or prostaglandin E0 (PGE0) (which were terminated prior to the onset of ischaemia) reduce myocardial infarct size arising from coronary artery occlusion (60 min) and reperfusion (120 min). "